A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 100 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) in children with asthma.

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].